Iparomlimab
Advanced Melanoma
Hebei Medical University Fourth HospitalPhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 73/ 100
Competitive context
34 Active assets in the Advanced Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PROPRANOLOL Sarah Weiss | Phase 2/3 | B |
Bcd-263 Biocad | Phase 3 | B |
Tuvonralimab Hebei Medical University Fourth Hospital | Phase 4 | B |
Vusolimogene Oderparepvec Replimune, Inc. | Phase 3 | B |
L-LYSINAMIDE, L-LYSYL-L-LYSYL-L-TRYPTOPHYL-L-TRYPTOPHYL-L-LYSYL-L-LYSYL-L-TRYPTOPHYL-.BETA.-PHENYL-L-PHENYLALANYL- Oslo University Hospital | Phase 2 | B |
View all 50 →
Same molecule, other indications
Iparomlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →